Four-Fold Increase in Direct Costs of Stroke Survivors With Spasticity Compared With Stroke Survivors Without Spasticity: The First Year After the Event
暂无分享,去创建一个
Jörgen Borg | Erik Lundström | Anja Smits | J. Borg | E. Lundström | A. Térent | A. Smits | Andreas Terént
[1] Imre Horváth,et al. 2 – Critical review of the literature , 1984 .
[2] J. R. Greenwood. Handbook of Neurological Rehabilitation , 2003 .
[3] H. Rodgers,et al. Study design and methods of the BoTULS trial: a randomised controlled trial to evaluate the clinical effect and cost effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A , 2008, Trials.
[4] K. Aho,et al. Cerebrovascular disease in the community: results of a WHO collaborative study. , 1980, Bulletin of the World Health Organization.
[5] Jeroen N. Struijs,et al. International Comparison of Stroke Cost Studies , 2004, Stroke.
[6] A. P. Moore,et al. Management of spasticity in adults: practical application of botulinum toxin , 2006, European journal of neurology.
[7] G. Cassel,et al. Abnormal Deviations in International Exchanges , 1918 .
[8] Jean-Michel Gracies,et al. Pathophysiology of spastic paresis. I: Paresis and soft tissue changes , 2005, Muscle & nerve.
[9] M. Leathley,et al. Reliability of the Tone Assessment Scale and the modified Ashworth scale as clinical tools for assessing poststroke spasticity. , 1999, Archives of physical medicine and rehabilitation.
[10] L. Ada,et al. Physiotherapy management of spasticity , 2001 .
[11] AD Pandyan,et al. Spasticity: Clinical perceptions, neurological realities and meaningful measurement , 2005, Disability and rehabilitation.
[12] Garth R. Johnson,et al. Upper Motor Neurone Syndrome and Spasticity: Clinical Management and Neurophysiology , 2008 .
[13] M Barnes,et al. BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A. , 2010, Health technology assessment.
[14] S. Gillard,et al. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. , 2005, Journal of rehabilitation medicine.
[15] M. Leathley,et al. Prevalence of spasticity post stroke , 2002, Clinical rehabilitation.
[16] R. Young,et al. Pathophysiology of spastic paresis , 1990 .
[17] J. W. Archer,et al. The Estimated Cost of Managing Focal Spasticity: A Physician Practice Patterns Survey , 2001, Neurorehabilitation and neural repair.
[18] B. Stegmayr,et al. Measuring stroke in the population: quality of routine statistics in comparison with a population-based stroke registry. , 1992, Neuroepidemiology.
[19] Bart Nooteboom,et al. An International Comparison , 2000 .
[20] Trends in Stroke Incidence and 10-Year Survival in Söderhamn, Sweden, 1975-2001 , 2003 .
[21] B. Norrving,et al. Stroke Incidence and Survival in the Beginning of the 21st Century in Southern Sweden: Comparisons With the Late 20th Century and Projections Into the Future , 2008, Stroke.
[22] F. Molteni,et al. Use of botulinum toxin type A in management of adult spasticity--a European consensus statement. , 2004, Journal of rehabilitation medicine.
[23] L. Widén Holmqvist,et al. Spasticity and Its Association with Functioning and Health-Related Quality of Life 18 Months after Stroke , 2006, Cerebrovascular Diseases.
[24] James Thomas,et al. International price comparisons based on purchasing power parity , 1999 .
[25] BOARD OF GOVERNORS OF THE FEDERAL RESERVE SYSTEM , 2000 .
[26] P. Rothwell,et al. Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature , 2009, Stroke.
[27] J. Gracies,et al. Pathophysiology of spastic paresis. II: Emergence of muscle overactivity , 2005, Muscle & nerve.
[28] T. Mulder,et al. Handbook of neurological rehabilitation , 2003 .
[29] A. Térent. A prospective epidemiological survey of cerebrovascular disease in a Swedish community. , 1979, Upsala journal of medical sciences.
[30] J. Borg,et al. Prevalence of disabling spasticity 1 year after first‐ever stroke , 2008, European journal of neurology.
[31] D. Wade. Upper motor neurone syndrome and spasticity. Clinical management and neurophysiology , 2001 .
[32] A V Milholland,et al. Medical assessment by a Delphi group opinion technic. , 1973, The New England journal of medicine.
[33] A. Térent. Increasing incidence of stroke among Swedish women. , 1988, Stroke.
[34] A. Jahangir,et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after stroke. , 2007, The Medical journal of Malaysia.
[35] Richard W. Bohannon,et al. Interrater reliability of a modified Ashworth scale of muscle spasticity. , 1987, Physical therapy.
[36] M. V. von Arbin,et al. Spasticity After Stroke: Its Occurrence and Association With Motor Impairments and Activity Limitations , 2003, Stroke.